Skip to search formSkip to main contentSkip to account menu

Lutetium Lu-177 Girentuximab

Known as: 177Lu-DOTA-cG250, Lutetium Lu-177-DOTA-Chimeric Monoclonal Antibody cG250, Lutetium-177 Labeled cG250 
A radioimmunoconjugate consisting of the chimeric monoclonal antibody cG250 linked to the low energy beta-emitting radioisotope Lutetium 177, via the… 
National Institutes of Health

Related topics

Related topics

1 relation
yttrium Y 90-DOTA-chimeric monoclonal antibody cG250

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Enhanced RCC cell killing with natural killer cells generated from CD34+ hematopoietic progenitor cells combined with mAb cG250
2016
2016
Improving treatment of Renal Cell Carcinoma with monoclonal antibody cG250
Monoclonal antibody G250 (mAbG250) recognizes a determinant on carbonic anhydrase IX (CAIX). CAIX is expressed by virtually all… 
2012
2012
200 Combination of sunitinib and mAb cG250 in nude mice bearing human renal cell carcinoma xenografts
2011
2011
A pilot study of the safety, efficacy, and effects on functional imaging of the combination of cG250 and sunitinib in patients (pts) with advanced renal cell carcinoma (RCC).
TPS142 Background: cG250 is an IgG1 kappa chimeric monoclonal antibody that binds to G250 (CAIX/MN), a heat-sensitive… 
2008
2008
Trials on preoperative chemotherapy in resectable colorectal liver metastases need prospective evaluation of predictive factors of response.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The author(s) indicated no potential conflicts of interest. REFERENCES 1… 
2002
2002
Organ and tumor dosimetry of Lu-177-DOTA-Tyr(3)-octreotate (Lu-TATE) and Y-90-DOTA-Tyr(3)-octreotide (Y-TOC): A preliminary study in 2 patients.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)